Modus Create Acquires Romanian Software Engineering Firm Clarisoft
10.1.2023 16:03:00 EET | Business Wire | Press release
Modus Create, a digital transformation consulting firm, announced today that it has acquired Clarisoft, a Romanian software engineering company with deep expertise in custom product development for enterprises.
This is Modus Create’s fifth acquisition in the last 12 months, topping off a year of accelerated growth and inclusion on the Inc. 5000 list for the eighth successive time. Since May, Modus Create has expanded its offerings through the acquisitions of software engineering company Tweag; product development firm Promptworks; and Atlassian consulting firms Atlas Authority and Twybee. The acquisition of Clarisoft represents Modus Create’s third acquisition in the European market.
Headquartered in Bucharest, Romania, Clarisoft is known for building quality software across enterprise, mid-market, and government clients worldwide, particularly in sectors such as healthcare, automotive, finance, and telecom. Its clients include organizations such as Cisco and Livongo Health.
Clarisoft’s CEO Bogdan Bucura will join Modus in a sales leadership role, and Development Director Mircea Enache will take on a delivery leadership role. Also joining Modus will be 40 senior engineers, designers, and project managers.
“We continue to add capabilities and talent that deepen Modus Create’s expertise as a leading global partner for product development. Adding Clarisoft to the team expands our European footprint and strengthens our offerings in enterprise software development, leading cloud platforms, and microservices delivery,” said Sarah McCasland, Chief Strategy Officer, Modus Create. “Most importantly, Clarisoft is a cultural fit that will seamlessly integrate with the Modus values of creating high-quality products for our clients.”
“By joining Modus Create, I saw an opportunity for Clarisoft to be a part of a bigger organization while still providing the type of service our clients expect,” said Bogdan Bucura, CEO, Clarisoft. “We will bring expertise in areas such as Microsoft Azure, broadening the scope of Modus’ already highly respected software engineering team. And we look forward to offering our clients the broader services Modus has in areas such as platform modernization and digital operations.”
About Modus Create
Modus Create is a digital consulting firm dedicated to helping clients build competitive advantage through digital innovation. We support organizations across their transformation journey with strategic consulting and full lifecycle product development. Our global team of strategists, designers, and technologists has created powerful digital experiences for some of the world’s biggest brands. Visit moduscreate.com to learn more.
About Clarisoft
Clarisoft Technologies is a top software development company with offices in Europe and the USA. We offer full-stack digital solutions for business and staff augmentation through outsourcing services in Romania. We provide high-quality and cost-effective custom software development and mobile application development services for enterprises.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005166/en/
Contact information
Ellie Behling
Modus Create
ellie.behling@moduscreate.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom